Clonz Biotech Profile
Key Indicators
- Authorised Capital ₹ 15.00 Cr
as on 03-07-2024
- Paid Up Capital ₹ 12.38 Cr
as on 03-07-2024
- Company Age 15 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 5.45 M
as on 03-07-2024
- Revenue 111025.00%
(FY 2023)
- Profit -10.70%
(FY 2023)
- Ebitda -50.45%
(FY 2023)
- Net Worth -221.15%
(FY 2023)
- Total Assets 60.74%
(FY 2023)
About Clonz Biotech
The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 15.00 Cr and a paid-up capital of Rs 12.38 Cr.
The company has closed loans amounting to ₹5.45 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Clonz Biotech Private Limited India is Mayank Agrawal as COMPANY SECRETARY. Narasimha Nedunuri, Venkatakrishna Vempalli, Pranesh Mathur, and Two other members serve as directors at the Company.
- CIN/LLPIN
U24231TG2009PTC065376
- Company No.
065376
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
08 Oct 2009
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Clonz Biotech Private Limited offer?
Clonz Biotech Private Limited offers a wide range of products and services, including Anti Cancer Injection, Bevacizumab.
Who are the key members and board of directors at Clonz Biotech?
Executive Team (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mayank Agrawal  | Company Secretary | 29-Jan-2024 | Current |
| Narasimha Nedunuri | Managing Director | 08-Oct-2009 | Current |
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Pranesh Mathur | Director | 09-Sep-2020 | Current |
| Venkatakrishna Vempalli | Director | 09-Sep-2020 | Current |
| Muralidhar Mamilla | Director | 08-Oct-2009 | Current |
| Venkata Vempalle | Director | 09-Sep-2020 | Current |
Financial Performance and Corporate Structure Insights of Clonz Biotech.
Clonz Biotech Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 111025% increase. The company also saw a substantial fall in profitability, with a 10.7% decrease in profit. The company's net worth observed a substantial decline by a decrease of 221.15%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Clonz Biotech?
In 2023, Clonz Biotech had a promoter holding of 31.09% and a public holding of 68.91%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Sri Krishna Pharmaceuticals LimitedActive 50 years 2 monthsVenkatakrishna Vempalli, Pranesh Mathur and 1 more are mutual person
Sri Krishna Biofert Private LimitedActive 29 years 3 monthsVenkatakrishna Vempalli and Venkata Vempalle are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Department Of Biotechnology Creation Date: 07 Aug 2012 | ₹5.45 M | Satisfied |
How Many Employees Work at Clonz Biotech?
Clonz Biotech has a workforce of 46 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Clonz Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Clonz Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
